vs
PHIBRO ANIMAL HEALTH CORP（PAHC）与UiPath, Inc.（PATH）财务数据对比。点击上方公司名可切换其他公司
UiPath, Inc.的季度营收约是PHIBRO ANIMAL HEALTH CORP的1.1倍（$411.1M vs $373.9M），UiPath, Inc.净利率更高（48.4% vs 7.3%，领先41.0%），PHIBRO ANIMAL HEALTH CORP同比增速更快（20.9% vs 15.9%），UiPath, Inc.自由现金流更多（$25.1M vs $8.3M），过去两年PHIBRO ANIMAL HEALTH CORP的营收复合增速更高（19.2% vs 0.7%）
菲宝罗动物保健公司是一家美国动物健康与矿物质营养企业，主营产品涵盖抗菌药、抗球虫药、驱虫药，以及畜禽营养补充剂、疫苗等。公司下设矿物质营养、功能材料、动物健康三大业务板块，收入主要来源于上述板块，业务遍及美国、拉美、加拿大、欧洲、中东、非洲及亚太地区。
UiPath是一家全球化软件企业，专注于开发人工智能、智能自动化及流程编排类软件，其产品支持用户搭建与调度AI代理，实现复杂业务流程、工作流的自动化运行，助力各行业客户提升运营效率、降低人力成本。
PAHC vs PATH — 直观对比
营收规模更大
PATH
是对方的1.1倍
$373.9M
营收增速更快
PAHC
高出5.0%
15.9%
净利率更高
PATH
高出41.0%
7.3%
自由现金流更多
PATH
多$16.9M
$8.3M
两年增速更快
PAHC
近两年复合增速
0.7%
损益表 — Q2 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $373.9M | $411.1M |
| 净利润 | $27.5M | $198.8M |
| 毛利率 | 35.5% | 83.3% |
| 营业利润率 | 13.5% | 3.2% |
| 净利率 | 7.3% | 48.4% |
| 营收同比 | 20.9% | 15.9% |
| 净利润同比 | 762.1% | 1966.2% |
| 每股收益（稀释后） | $0.67 | $0.37 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PAHCPATH
| Q4 25 | $373.9M | $411.1M | ||
| Q3 25 | $363.9M | $361.7M | ||
| Q2 25 | $378.7M | $356.6M | ||
| Q1 25 | $347.8M | $423.6M | ||
| Q4 24 | $309.3M | $354.7M | ||
| Q3 24 | $260.4M | $316.3M | ||
| Q2 24 | $273.2M | $335.1M | ||
| Q1 24 | $263.2M | $405.3M |
净利润PAHCPATH
| Q4 25 | $27.5M | $198.8M | ||
| Q3 25 | $26.5M | $1.6M | ||
| Q2 25 | $17.2M | $-22.6M | ||
| Q1 25 | $20.9M | $51.8M | ||
| Q4 24 | $3.2M | $-10.7M | ||
| Q3 24 | $7.0M | $-86.1M | ||
| Q2 24 | $752.0K | $-28.7M | ||
| Q1 24 | $8.4M | $33.9M |
毛利率PAHCPATH
| Q4 25 | 35.5% | 83.3% | ||
| Q3 25 | 32.9% | 82.2% | ||
| Q2 25 | 29.0% | 82.1% | ||
| Q1 25 | 30.1% | 84.8% | ||
| Q4 24 | 32.9% | 82.0% | ||
| Q3 24 | 32.1% | 80.0% | ||
| Q2 24 | 31.9% | 83.5% | ||
| Q1 24 | 30.2% | 86.8% |
营业利润率PAHCPATH
| Q4 25 | 13.5% | 3.2% | ||
| Q3 25 | 14.1% | -5.6% | ||
| Q2 25 | 8.9% | -4.6% | ||
| Q1 25 | 9.6% | 7.9% | ||
| Q4 24 | 8.3% | -12.2% | ||
| Q3 24 | 6.8% | -32.7% | ||
| Q2 24 | 6.7% | -14.8% | ||
| Q1 24 | 7.6% | 3.7% |
净利率PAHCPATH
| Q4 25 | 7.3% | 48.4% | ||
| Q3 25 | 7.3% | 0.4% | ||
| Q2 25 | 4.5% | -6.3% | ||
| Q1 25 | 6.0% | 12.2% | ||
| Q4 24 | 1.0% | -3.0% | ||
| Q3 24 | 2.7% | -27.2% | ||
| Q2 24 | 0.3% | -8.6% | ||
| Q1 24 | 3.2% | 8.4% |
每股收益（稀释后）PAHCPATH
| Q4 25 | $0.67 | $0.37 | ||
| Q3 25 | $0.65 | $0.00 | ||
| Q2 25 | $0.43 | $-0.04 | ||
| Q1 25 | $0.51 | $0.09 | ||
| Q4 24 | $0.08 | $-0.02 | ||
| Q3 24 | $0.17 | $-0.15 | ||
| Q2 24 | $0.02 | $-0.05 | ||
| Q1 24 | $0.21 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $74.5M | $1.4B |
| 总债务越低越好 | $624.2M | — |
| 股东权益账面价值 | $332.4M | $1.9B |
| 总资产 | $1.4B | $2.9B |
| 负债/权益比越低杠杆越低 | 1.88× | — |
8季度趋势，按日历期对齐
现金及短期投资PAHCPATH
| Q4 25 | $74.5M | $1.4B | ||
| Q3 25 | $85.3M | $1.4B | ||
| Q2 25 | $77.0M | $1.6B | ||
| Q1 25 | $70.4M | $1.6B | ||
| Q4 24 | $67.1M | $1.6B | ||
| Q3 24 | $89.8M | $1.7B | ||
| Q2 24 | $114.6M | $1.9B | ||
| Q1 24 | $98.7M | $1.9B |
总债务PAHCPATH
| Q4 25 | $624.2M | — | ||
| Q3 25 | $628.0M | — | ||
| Q2 25 | $631.7M | — | ||
| Q1 25 | $635.4M | — | ||
| Q4 24 | $639.1M | — | ||
| Q3 24 | $295.2M | — | ||
| Q2 24 | $312.1M | — | ||
| Q1 24 | — | — |
股东权益PAHCPATH
| Q4 25 | $332.4M | $1.9B | ||
| Q3 25 | $311.7M | $1.7B | ||
| Q2 25 | $285.7M | $1.7B | ||
| Q1 25 | $266.0M | $1.8B | ||
| Q4 24 | $246.8M | $1.7B | ||
| Q3 24 | $258.5M | $1.8B | ||
| Q2 24 | $256.6M | $2.0B | ||
| Q1 24 | $270.1M | $2.0B |
总资产PAHCPATH
| Q4 25 | $1.4B | $2.9B | ||
| Q3 25 | $1.4B | $2.6B | ||
| Q2 25 | $1.4B | $2.6B | ||
| Q1 25 | $1.3B | $2.9B | ||
| Q4 24 | $1.3B | $2.7B | ||
| Q3 24 | $966.3M | $2.7B | ||
| Q2 24 | $982.2M | $2.8B | ||
| Q1 24 | $979.0M | $3.0B |
负债/权益比PAHCPATH
| Q4 25 | 1.88× | — | ||
| Q3 25 | 2.01× | — | ||
| Q2 25 | 2.21× | — | ||
| Q1 25 | 2.39× | — | ||
| Q4 24 | 2.59× | — | ||
| Q3 24 | 1.14× | — | ||
| Q2 24 | 1.22× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.4M | $28.3M |
| 自由现金流经营现金流 - 资本支出 | $8.3M | $25.1M |
| 自由现金流率自由现金流/营收 | 2.2% | 6.1% |
| 资本支出强度资本支出/营收 | 3.0% | 0.8% |
| 现金转化率经营现金流/净利润 | 0.70× | 0.14× |
| 过去12个月自由现金流最近4个季度 | $47.3M | — |
8季度趋势，按日历期对齐
经营现金流PAHCPATH
| Q4 25 | $19.4M | $28.3M | ||
| Q3 25 | $9.3M | $41.6M | ||
| Q2 25 | $21.3M | $119.0M | ||
| Q1 25 | $43.2M | $146.1M | ||
| Q4 24 | $3.1M | $28.1M | ||
| Q3 24 | $12.6M | $46.4M | ||
| Q2 24 | $28.4M | $100.0M | ||
| Q1 24 | $11.4M | $145.6M |
自由现金流PAHCPATH
| Q4 25 | $8.3M | $25.1M | ||
| Q3 25 | $-4.5M | — | ||
| Q2 25 | $8.1M | $106.2M | ||
| Q1 25 | $35.4M | $138.7M | ||
| Q4 24 | $-4.7M | $23.2M | ||
| Q3 24 | $3.0M | $45.0M | ||
| Q2 24 | $15.4M | $98.8M | ||
| Q1 24 | $1.7M | $141.8M |
自由现金流率PAHCPATH
| Q4 25 | 2.2% | 6.1% | ||
| Q3 25 | -1.2% | — | ||
| Q2 25 | 2.1% | 29.8% | ||
| Q1 25 | 10.2% | 32.7% | ||
| Q4 24 | -1.5% | 6.5% | ||
| Q3 24 | 1.2% | 14.2% | ||
| Q2 24 | 5.6% | 29.5% | ||
| Q1 24 | 0.6% | 35.0% |
资本支出强度PAHCPATH
| Q4 25 | 3.0% | 0.8% | ||
| Q3 25 | 3.8% | 0.0% | ||
| Q2 25 | 3.5% | 3.6% | ||
| Q1 25 | 2.2% | 1.7% | ||
| Q4 24 | 2.5% | 1.4% | ||
| Q3 24 | 3.7% | 0.4% | ||
| Q2 24 | 4.8% | 0.4% | ||
| Q1 24 | 3.7% | 0.9% |
现金转化率PAHCPATH
| Q4 25 | 0.70× | 0.14× | ||
| Q3 25 | 0.35× | 26.25× | ||
| Q2 25 | 1.24× | — | ||
| Q1 25 | 2.07× | 2.82× | ||
| Q4 24 | 0.97× | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 37.80× | — | ||
| Q1 24 | 1.36× | 4.29× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PAHC
| Medicated Feed Additives And Others | $202.1M | 54% |
| Mineral Nutrition | $68.9M | 18% |
| Nutritional Specialties | $50.2M | 13% |
| Vaccines | $37.6M | 10% |
| Performance Products | $15.0M | 4% |
PATH
| Subscription Services | $247.6M | 60% |
| License | $150.0M | 36% |
| Professional Services And Other | $13.5M | 3% |
